Pharma & Healthcare
Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Research Report 2026
- Feb 24, 26
- ID: 719571
- Pages: 121
- Figures: 119
- Views: 3
This report delivers a comprehensive overview of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antiviral Drugs for the Treatment of Hepatitis C (HCV). The Antiviral Drugs for the Treatment of Hepatitis C (HCV) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
Asegua Therapeutics
Merck
AbbVie
Bristol Myers Squibb
Ascletis Pharma
Kawin Technology
YiChang HEC ChangJiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Cosunter pharmaceutical
Beijing Sihuan Pharmaceutical
Segment by Type
NS5A Inhibitors
NS5B Polymerase Inhibitors
NS3/4A Protease Inhibitors
Other
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
Asegua Therapeutics
Merck
AbbVie
Bristol Myers Squibb
Ascletis Pharma
Kawin Technology
YiChang HEC ChangJiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Cosunter pharmaceutical
Beijing Sihuan Pharmaceutical
Segment by Type
NS5A Inhibitors
NS5B Polymerase Inhibitors
NS3/4A Protease Inhibitors
Other
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Overview
1.1 Product Definition
1.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type
1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type: 2025 vs 2032
1.2.2 NS5A Inhibitors
1.2.3 NS5B Polymerase Inhibitors
1.2.4 NS3/4A Protease Inhibitors
1.2.5 Other
1.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application
1.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Estimates and Forecasts
1.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue 2021–2032
1.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales 2021–2032
1.4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competition by Manufacturers
2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Types and Applications
2.7 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Entry into the Industry
2.8 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation and Trends
2.8.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players Market Share by Revenue
2.8.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Scenario by Region
3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021–2032
3.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021–2026
3.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2027–2032
3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021–2032
3.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021–2026
3.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2027–2032
3.4 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.4.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.4.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.5.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.5.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Region
3.6.1 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021–2032)
3.6.3 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.7.1 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.7.3 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021–2032)
4.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021–2026)
4.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027–2032)
4.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021–2032)
4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021–2032)
4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021–2026)
4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027–2032)
4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021–2032)
4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021–2032)
5.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021–2026)
5.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027–2032)
5.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021–2032)
5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021–2032)
5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021–2026)
5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027–2032)
5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021–2032)
5.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Asegua Therapeutics
6.2.1 Asegua Therapeutics Company Information
6.2.2 Asegua Therapeutics Description and Business Overview
6.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.2.5 Asegua Therapeutics Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Bristol Myers Squibb
6.5.1 Bristol Myers Squibb Company Information
6.5.2 Bristol Myers Squibb Description and Business Overview
6.5.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.5.5 Bristol Myers Squibb Recent Developments/Updates
6.6 Ascletis Pharma
6.6.1 Ascletis Pharma Company Information
6.6.2 Ascletis Pharma Description and Business Overview
6.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.6.5 Ascletis Pharma Recent Developments/Updates
6.7 Kawin Technology
6.7.1 Kawin Technology Company Information
6.7.2 Kawin Technology Description and Business Overview
6.7.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
6.8 YiChang HEC ChangJiang Pharmaceutical
6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information
6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
6.8.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.9 Sanhome Pharmaceutical
6.9.1 Sanhome Pharmaceutical Company Information
6.9.2 Sanhome Pharmaceutical Description and Business Overview
6.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.9.5 Sanhome Pharmaceutical Recent Developments/Updates
6.10 Chia Tai Tianqing Pharmaceutical
6.10.1 Chia Tai Tianqing Pharmaceutical Company Information
6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.11 Cosunter pharmaceutical
6.11.1 Cosunter pharmaceutical Company Information
6.11.2 Cosunter pharmaceutical Description and Business Overview
6.11.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.11.5 Cosunter pharmaceutical Recent Developments/Updates
6.12 Beijing Sihuan Pharmaceutical
6.12.1 Beijing Sihuan Pharmaceutical Company Information
6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.12.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Chain Analysis
7.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process Analysis
7.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales and Marketing
7.4.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels
7.4.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors
7.5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customer Analysis
8 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Dynamics
8.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends
8.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers
8.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges
8.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type
1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type: 2025 vs 2032
1.2.2 NS5A Inhibitors
1.2.3 NS5B Polymerase Inhibitors
1.2.4 NS3/4A Protease Inhibitors
1.2.5 Other
1.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application
1.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Estimates and Forecasts
1.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue 2021–2032
1.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales 2021–2032
1.4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competition by Manufacturers
2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Types and Applications
2.7 Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Entry into the Industry
2.8 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation and Trends
2.8.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players Market Share by Revenue
2.8.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Scenario by Region
3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021–2032
3.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021–2026
3.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2027–2032
3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021–2032
3.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021–2026
3.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2027–2032
3.4 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.4.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.4.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.5.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.5.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Region
3.6.1 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021–2032)
3.6.3 Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.7.1 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.7.3 Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021–2032)
4.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021–2026)
4.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027–2032)
4.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021–2032)
4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021–2032)
4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021–2026)
4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027–2032)
4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021–2032)
4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021–2032)
5.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021–2026)
5.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027–2032)
5.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021–2032)
5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021–2032)
5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021–2026)
5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027–2032)
5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021–2032)
5.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Asegua Therapeutics
6.2.1 Asegua Therapeutics Company Information
6.2.2 Asegua Therapeutics Description and Business Overview
6.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.2.5 Asegua Therapeutics Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Bristol Myers Squibb
6.5.1 Bristol Myers Squibb Company Information
6.5.2 Bristol Myers Squibb Description and Business Overview
6.5.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.5.5 Bristol Myers Squibb Recent Developments/Updates
6.6 Ascletis Pharma
6.6.1 Ascletis Pharma Company Information
6.6.2 Ascletis Pharma Description and Business Overview
6.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.6.5 Ascletis Pharma Recent Developments/Updates
6.7 Kawin Technology
6.7.1 Kawin Technology Company Information
6.7.2 Kawin Technology Description and Business Overview
6.7.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
6.8 YiChang HEC ChangJiang Pharmaceutical
6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information
6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
6.8.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.9 Sanhome Pharmaceutical
6.9.1 Sanhome Pharmaceutical Company Information
6.9.2 Sanhome Pharmaceutical Description and Business Overview
6.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.9.5 Sanhome Pharmaceutical Recent Developments/Updates
6.10 Chia Tai Tianqing Pharmaceutical
6.10.1 Chia Tai Tianqing Pharmaceutical Company Information
6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.11 Cosunter pharmaceutical
6.11.1 Cosunter pharmaceutical Company Information
6.11.2 Cosunter pharmaceutical Description and Business Overview
6.11.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.11.5 Cosunter pharmaceutical Recent Developments/Updates
6.12 Beijing Sihuan Pharmaceutical
6.12.1 Beijing Sihuan Pharmaceutical Company Information
6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.12.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Chain Analysis
7.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process Analysis
7.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales and Marketing
7.4.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels
7.4.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors
7.5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customer Analysis
8 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Dynamics
8.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends
8.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers
8.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges
8.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Types and Applications
Table 12. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2021–2026
Table 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021–2026)
Table 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2027–2032
Table 20. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2027–2032)
Table 21. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021–2026)
Table 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2027–2032)
Table 25. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 27. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 28. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 32. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 33. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 42. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2021–2026)
Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2027–2032)
Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021–2026)
Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2027–2032)
Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021–2026)
Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2027–2032)
Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2021–2026)
Table 61. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2027–2032)
Table 62. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021–2026)
Table 63. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2027–2032)
Table 64. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021–2026)
Table 67. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2027–2032)
Table 68. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. Asegua Therapeutics Company Information
Table 76. Asegua Therapeutics Description and Business Overview
Table 77. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 79. Asegua Therapeutics Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 84. Merck Recent Developments/Updates
Table 85. AbbVie Company Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 89. AbbVie Recent Developments/Updates
Table 90. Bristol Myers Squibb Company Information
Table 91. Bristol Myers Squibb Description and Business Overview
Table 92. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 94. Bristol Myers Squibb Recent Developments/Updates
Table 95. Ascletis Pharma Company Information
Table 96. Ascletis Pharma Description and Business Overview
Table 97. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 99. Ascletis Pharma Recent Developments/Updates
Table 100. Kawin Technology Company Information
Table 101. Kawin Technology Description and Business Overview
Table 102. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 104. Kawin Technology Recent Developments/Updates
Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information
Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
Table 107. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
Table 110. Sanhome Pharmaceutical Company Information
Table 111. Sanhome Pharmaceutical Description and Business Overview
Table 112. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 114. Sanhome Pharmaceutical Recent Developments/Updates
Table 115. Chia Tai Tianqing Pharmaceutical Company Information
Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 117. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 120. Cosunter pharmaceutical Company Information
Table 121. Cosunter pharmaceutical Description and Business Overview
Table 122. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 124. Cosunter pharmaceutical Recent Developments/Updates
Table 125. Beijing Sihuan Pharmaceutical Company Information
Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview
Table 127. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List
Table 133. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List
Table 134. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Trends
Table 135. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers
Table 136. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges
Table 137. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antiviral Drugs for the Treatment of Hepatitis C (HCV)
Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Type: 2025 & 2032
Figure 4. NS5A Inhibitors Product Picture
Figure 5. NS5B Polymerase Inhibitors Product Picture
Figure 6. NS3/4A Protease Inhibitors Product Picture
Figure 7. Other Product Picture
Figure 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Application: 2025 & 2032
Figure 10. Hospital and Clinic
Figure 11. Pharmacy
Figure 12. Other
Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size (US$ Million), 2021–2032
Figure 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), 2021–2032
Figure 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit), 2021–2032
Figure 17. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Report Years Considered
Figure 18. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Manufacturers in 2025
Figure 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players: Market Share by Revenue in Antiviral Drugs for the Treatment of Hepatitis C (HCV) in 2025
Figure 21. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 24. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 25. United States Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 28. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 29. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021–2032)
Figure 36. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 44. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2021–2032)
Figure 55. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2021–2032)
Figure 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2021–2032)
Figure 58. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2021–2032)
Figure 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2021–2032)
Figure 60. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Product Types and Applications
Table 12. Global Key Manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2021–2026
Table 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021–2026)
Table 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2027–2032
Table 20. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2027–2032)
Table 21. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021–2026)
Table 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2027–2032)
Table 25. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 27. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 28. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 32. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 33. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 42. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2021–2026)
Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Type (2027–2032)
Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021–2026)
Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2027–2032)
Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021–2026)
Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2027–2032)
Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2021–2026)
Table 61. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units) by Application (2027–2032)
Table 62. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021–2026)
Table 63. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2027–2032)
Table 64. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021–2026)
Table 67. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2027–2032)
Table 68. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. Asegua Therapeutics Company Information
Table 76. Asegua Therapeutics Description and Business Overview
Table 77. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 79. Asegua Therapeutics Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 84. Merck Recent Developments/Updates
Table 85. AbbVie Company Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 89. AbbVie Recent Developments/Updates
Table 90. Bristol Myers Squibb Company Information
Table 91. Bristol Myers Squibb Description and Business Overview
Table 92. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 94. Bristol Myers Squibb Recent Developments/Updates
Table 95. Ascletis Pharma Company Information
Table 96. Ascletis Pharma Description and Business Overview
Table 97. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 99. Ascletis Pharma Recent Developments/Updates
Table 100. Kawin Technology Company Information
Table 101. Kawin Technology Description and Business Overview
Table 102. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 104. Kawin Technology Recent Developments/Updates
Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information
Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
Table 107. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
Table 110. Sanhome Pharmaceutical Company Information
Table 111. Sanhome Pharmaceutical Description and Business Overview
Table 112. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 114. Sanhome Pharmaceutical Recent Developments/Updates
Table 115. Chia Tai Tianqing Pharmaceutical Company Information
Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 117. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 120. Cosunter pharmaceutical Company Information
Table 121. Cosunter pharmaceutical Description and Business Overview
Table 122. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 124. Cosunter pharmaceutical Recent Developments/Updates
Table 125. Beijing Sihuan Pharmaceutical Company Information
Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview
Table 127. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product
Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List
Table 133. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List
Table 134. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Trends
Table 135. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Drivers
Table 136. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Challenges
Table 137. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antiviral Drugs for the Treatment of Hepatitis C (HCV)
Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Type: 2025 & 2032
Figure 4. NS5A Inhibitors Product Picture
Figure 5. NS5B Polymerase Inhibitors Product Picture
Figure 6. NS3/4A Protease Inhibitors Product Picture
Figure 7. Other Product Picture
Figure 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Application: 2025 & 2032
Figure 10. Hospital and Clinic
Figure 11. Pharmacy
Figure 12. Other
Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size (US$ Million), 2021–2032
Figure 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), 2021–2032
Figure 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit), 2021–2032
Figure 17. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Report Years Considered
Figure 18. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Manufacturers in 2025
Figure 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players: Market Share by Revenue in Antiviral Drugs for the Treatment of Hepatitis C (HCV) in 2025
Figure 21. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 24. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 25. United States Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 28. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 29. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021–2032)
Figure 36. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 44. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2021–2032)
Figure 55. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Type (2021–2032)
Figure 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2021–2032)
Figure 58. Global Revenue Market Share of Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application (2021–2032)
Figure 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (US$/Unit) by Application (2021–2032)
Figure 60. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232